Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
6.71
+0.02 (0.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Acrivon Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -76.98 | -60.39 | -31.17 | -16.24 | -5.31 |
| Depreciation & Amortization | 0.85 | 0.54 | 0.36 | 0.04 | 0.01 |
| Loss (Gain) From Sale of Investments | -3.56 | -3.32 | -0.7 | - | - |
| Stock-Based Compensation | 13.64 | 11.62 | 2.19 | 0.5 | 0 |
| Other Operating Activities | 0.88 | 0.78 | 0.73 | 1.4 | 2.17 |
| Change in Accounts Payable | -0.19 | 3.61 | -0.25 | 0.8 | 0.08 |
| Change in Other Net Operating Assets | 4.67 | 4.53 | -1.29 | -0.47 | 0.24 |
| Operating Cash Flow | -60.68 | -42.64 | -30.12 | -13.98 | -2.8 |
| Capital Expenditures | -3.09 | -1.29 | -2.17 | -0.24 | -0.02 |
| Investment in Securities | -42.56 | 52.01 | -139.51 | - | - |
| Investing Cash Flow | -45.65 | 50.72 | -141.68 | -0.24 | -0.02 |
| Long-Term Debt Issued | - | - | - | - | 0.06 |
| Net Debt Issued (Repaid) | - | - | - | - | 0.06 |
| Issuance of Common Stock | 70.41 | 0.78 | 104.48 | 0 | - |
| Repurchase of Common Stock | -3.17 | -1.3 | - | - | - |
| Other Financing Activities | 52.43 | -1.03 | -2.77 | - | - |
| Financing Cash Flow | 119.66 | -1.55 | 101.71 | 112.22 | 2.89 |
| Net Cash Flow | 13.34 | 6.52 | -70.08 | 98 | 0.07 |
| Free Cash Flow | -63.77 | -43.93 | -32.28 | -14.22 | -2.82 |
| Free Cash Flow Per Share | -2.14 | -1.99 | -7.83 | -8.16 | -1.97 |
| Levered Free Cash Flow | -35.79 | -22.33 | -20.03 | -8.79 | - |
| Unlevered Free Cash Flow | -35.79 | -22.33 | -20.03 | -8.79 | - |
| Change in Net Working Capital | -6.13 | -8.75 | -0 | -1.03 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.